Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium release-activated calcium (CRAC) channel at AACR-NCI-EORTC International Conference, USA

La Chaux-de-Fonds, Switzerland, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor in hematological malignancies and solid tumors

--- Three preclinical poster presentations highlight the potential of RP4010 alone and in combination with approved drugs for treating hematological malignancies and solid tumors

--- A multi-center Phase I/IB dose-escalation trial evaluating the safety and efficacy of RP4010, a CRAC channel inhibitor in patients with relapsed or refractory Non-Hodgkin Lymphoma (NHL) is currently ongoing in USA (ClinicalTrials.gov Identifier: NCT03119467)

About RP4010:

RP4010 is a novel first-in-class oral small molecule inhibitor of calcium release activated calcium (CRAC) channel pathway with demonstrated preclinical activity in a broad range of cancers. Aberrant CRAC channel activity has been linked to various autoimmune disorders and certain cancers via the NFAT pathway. In addition, the blockage of store-operated calcium entry (SOCE) by a CRAC channel inhibitor could suppress tumor growth through a number of mechanisms, including the inhibition of calcium-dependent activation of Akt/NF-κB and ERK 1/2 pathways.

Details of the poster presentations:

-- Poster Title: Antitumor activity of RP4010, a novel small-molecule inhibitor of the calcium release-activated calcium (CRAC) channel pathway

  • Session Title: Poster Session B
  • Session Category: Therapeutic Agents: Other Topics
  • Session Date & Time: Sunday, October 29, 2017; 12:30 PM – 4:00 PM
  • Location: Hall E, Pennsylvania Convention Center
  • Poster Board Number: 127
-- Poster Title: Efficacy of RP4010, a calcium release-activated calcium (CRAC) inhibitor, in preclinical models of DLBCL

- Session Title: Poster Session B
- Session Category: Therapeutic Agents: Other Topics
- Session Date & Time: Sunday, October 29, 2017; 12:30 PM – 4:00 PM
- Location: Hall E, Pennsylvania Convention Center
- Poster Board Number: 128

-- Poster Title: Targeting Orai1-mediated store-operated Ca\(^{2+}\) entry by a novel compound RP4010 for antiproliferative activity against Esophagus Squamous Cell Carcinoma

- Session Title: Poster Session B
- Session Category: New Molecular Targets
- Session Date & Time: Sunday, October 29, 2017; 12:30 PM – 4:00 PM
- Location: Hall E, Pennsylvania Convention Center
- Poster Board Number: 62

About Rhizen Pharmaceuticals S.A.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen’s website, [www.rhizen.com](http://www.rhizen.com).

Contact: Kumar V. Penmetsa, Ph.D.
Executive Vice President, Corporate Development
Rhizen Pharmaceuticals S.A.
Telephone: +1-267-207-5707
Email: kvp@rhizen.com